Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

Exclusion Criteria

• •Patients with a life expectancy ≤ 16 weeks
• •Patients with ocular melanoma
• •Patients with symptomatic and/or unstable brain metastasis during the last 3 months (90 days) prior to Day 1, Cycle 1
• •Patients with a history of allergic reactions or hypersensitivity to somatostatin analogues
• •Patients with a documented history of HIV, active hepatitis B or C infection
• •Female patients who are pregnant or lactating
• •Patients who are receiving hormonal therapy (with the exception of hormone replacement therapy and hormonal contraceptives), systemic steroids, immunosuppressive therapy or coumadin (low molecular weight heparin is permitted)
• •Patients with grade ≥2 peripheral neuropathy (CTCAE criteria)
• •Patients in whom a proper central line cannot be established